D2 Receptor Ligands With Biased β-Arrestin and cAMP Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipsychotic drugs targeting dopamine D2 receptors lack selectivity, leading to diverse effects on GPCR receptors and undesirable side effects, necessitating the development of functionally selective ligands that modulate the β-arrestin and cAMP pathways to improve clinical efficacy and safety.
Innovation Solution
Development of novel compounds that exhibit functional selectivity at dopamine D2 receptors, acting as agonists, antagonists, or partial agonists, specifically targeting the β-arrestin or cAMP pathways to treat disorders associated with dopamine receptors while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional dopamine agonists (e.g., bromocriptine, pergolide, cabergoline) are used to treat restless legs syndrome, then they can address dopamine deficiency, but they cause unacceptable side effects including nausea, vomiting, hypotension, and hallucinations
Solution Approach 1:
The patent applies local quality by designing ligands with selective affinity for D2 receptors in specific brain regions (mesolimbic and mesocortical pathways) while avoiding non-selective binding to D2 receptors throughout the brain. This regional selectivity is achieved through specific molecular structure modifications that enable the ligand to cross the blood-brain barrier and bind preferentially to target receptors, thereby producing therapeutic effects in affected regions without causing systemic side effects associated with broad D2 receptor activation.
Solution Approach 2:
The patent employs an intermediary approach by developing novel ligand molecules that act as selective mediators between the administered drug and the D2 receptors. These ligands serve as intermediate compounds that facilitate selective receptor binding through their unique molecular structures, which include specific functional groups and stereochemical configurations that enable preferential interaction with target D2 receptors while minimizing off-target effects.
2Adaptability or versatility
If non-selective D2 receptor agonists are administered, then dopamine deficiency can be addressed, but the lack of selectivity leads to activation of non-target receptors causing adverse reactions
Solution Approach 1:
The patent implements local quality by confining the binding activity of the ligand to specific D2 receptor subtypes and brain regions. The molecular structure is engineered with specific pharmacophoric elements that provide selective affinity for D2 receptors in the mesolimbic and mesocortical pathways, creating a localized effect that spares other receptor systems and prevents adverse reactions associated with non-selective binding.
Solution Approach 2:
The patent applies parameter changes by modifying key molecular parameters of the ligand structure, including stereochemistry, functional group composition, and molecular weight, to optimize selectivity for D2 receptors. These parameter adjustments enable the ligand to achieve high binding affinity for target receptors while reducing affinity for non-target receptors, thereby maintaining adaptability for therapeutic effect while minimizing adverse reactions.
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0- arrestin pathway and/or on the cAMP pathway.